OCS
Oculis Holding
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About OCS
Oculis Holding Ag
A company that develops drugs to treat eye diseases
Bahnhofstrasse 7, CH-6300, Zug, Switzerland
--
Oculis Holding AG was incorporated under the laws of Switzerland on December 11, 2017. The Company is a clinical-stage biopharmaceutical company headquartered in Switzerland with extensive expertise in therapies for the treatment of eye diseases and is involved in the development of innovative drug candidates with the potential to address many eye diseases. Their focus is on advancing therapeutic candidates to treat major ophthalmic diseases that lead to vision loss, blindness or reduced quality of life. Their clinical portfolio currently includes three therapeutic drug candidates: OCS-01, OCS-02 and OCS-05.
Company Financials
EPS
OCS has released its 2022 Q2 earnings. EPS was reported at 0.01, versus the expected 0.00, beating expectations. The chart below visualizes how OCS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCS has released its 2024 Q4 earnings report, with revenue of 3.31K, reflecting a YoY change of -98.50%, and net profit of -31.60M, showing a YoY change of -112.50%. The Sankey diagram below clearly presents OCS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
